VIDEO: Weight-loss effects ‘patients have been waiting for’
Click Here to Manage Email Alerts
In this video exclusive, Healio | Endocrine Today Co-editor Sangeeta R. Kashyap, MD, talks with Thomas A. Wadden, PhD, about the effects of semaglutide on weight loss and obesity-related comorbidities.
Kashyap is a physician scientist in the Endocrinology Institute at Cleveland Clinic and professor of medicine at the Cleveland Clinic Lerner College of Medicine. Wadden is the Albert J. Stunkard Professor of Psychology in Psychiatry and former director of the Center for Weight and Eating Disorders at the Perelman School of Medicine, University of Pennsylvania. He is an investigator in the STEP clinical trial program assessing use of semaglutide (Wegovy, Novo Nordisk) for weight loss.
Semaglutide provides about double the weight loss of most other weight-loss drugs and behavioral therapies, Wadden said. Larger weight losses yield larger improvements in obesity-related comorbidities.
“Weight losses of this magnitude are what patients with overweight and obesity are looking for,” Wadden said. “Patients have been waiting for medications that can produce weight loss of 15% or more.”
Collapse
Click Here to Manage Email Alerts